Literature DB >> 8821542

Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.

M A Vieira-Coelho1, P Soares-da-Silva.   

Abstract

1. The present work describes the catechol-O-methyltransferase (COMT) activities in the liver and kidney of developing and adult rats (aged 3, 6, 9, 18, 30 and 60 days; n = 5 per group) and evaluates the enzyme sensitivity to inhibition by tolcapone, a reversible COMT inhibitor. 2. COMT activity, evaluated by the ability to methylate adrenaline to metanephrine, was determined in liver and kidney homogenates prepared in 0.5 mM phosphate buffer (pH = 7.8) containing pargyline (0.1 mM), MgCl2 (0.1 mM), EGTA (1 mM) and S-adenosyl-L-methionine (0.1 mM). Vmax (in nmol mg-1 protein h-1) of liver COMT was found to decrease gradually with age, from 5.3 +/- 0.5 at the age of 3 days up to 2.9 +/- 0.2 at the age of 60 days; for the same age range, Km values (in microM; geometric means with 95% confidence limits) increased from 3.3 (1.0, 7.5) up to 13.1 (2.1, 24.1). At the age of 3 days, Vmax values for kidney COMT (2.6 +/- 0.1) were lower than those for the liver COMT. However, Vmax values for kidney COMT were found to increase up to 6.2 +/- 0.6 at the age of 18 days and then declined by 44% at the age of 30 and 60 days. In kidney, aging was also accompanied by an increase in Km values for COMT (from 2.7 [1.1, 4.3] up to 24.0 [11.7, 36.3]). 3. The sensitivity of liver and renal COMT activity to tolcapone was markedly dependent on the age, 3-days old rats being more sensitive to tolcapone than older animals. The IC50 values (in nM) for inhibition of liver COMT by tolcapone increased gradually with age, from 41 (26, 65) at the age of 3 days up to 720 (640, 800) at the age of 60 days. As was found in the liver, IC50 values (in nM) for inhibition of kidney COMT by tolcapone also increased with age, from 8 (6, 10) at the age of 3 days up to 177 (131, 240) at the age of 60 days. In all experimental groups, the IC50 values for inhibition of liver COMT by tolcapone was higher than those for kidney COMT. 4. In conclusion, these results suggest that aging is accompanied by a decrease in liver and kidney COMT affinity for the substrate (evidenced by the increase in Km values) and a decrease in sensitivity towards inhibition by tolcapone (evidenced by the increase in IC50 values). Furthermore, kidney COMT is shown to be more sensitive to inhibition by tolcapone than liver COMT, irrespective of the age of the animal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821542      PMCID: PMC1909301          DOI: 10.1111/j.1476-5381.1996.tb15220.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

Review 1.  Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Authors:  H C Guldberg; C A Marsden
Journal:  Pharmacol Rev       Date:  1975-06       Impact factor: 25.468

2.  Enzymatic O-methylation of epinephrine and other catechols.

Authors:  J AXELROD; R TOMCHICK
Journal:  J Biol Chem       Date:  1958-09       Impact factor: 5.157

Review 3.  Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters.

Authors:  J A Roth
Journal:  Rev Physiol Biochem Pharmacol       Date:  1992       Impact factor: 5.545

4.  Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats.

Authors:  G Zürcher; H H Keller; R Kettler; J Borgulya; E P Bonetti; R Eigenmann; M Da Prada
Journal:  Adv Neurol       Date:  1990

5.  Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.

Authors:  G Zürcher; A Colzi; M Da Prada
Journal:  J Neural Transm Suppl       Date:  1990

Review 6.  New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

Authors:  P T Männistö; S Kaakkola
Journal:  Trends Pharmacol Sci       Date:  1989-02       Impact factor: 14.819

7.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 8.  Catecholamine metabolism: basic aspects and clinical significance.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1985-12       Impact factor: 25.468

Review 9.  Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines.

Authors:  J Axelrod
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

10.  Solubilization and partial purification of particulate catechol-O-methyltransferase from rat liver.

Authors:  J H Tong; A D'Iorio
Journal:  Can J Biochem       Date:  1977-10
View more
  8 in total

Review 1.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

2.  Catechol-O-methyltransferase activity in erythrocytes from patients with eating disorders.

Authors:  T Amorim-Barbosa; M P Serrão; I Brandão; M A Vieira-Coelho
Journal:  Eat Weight Disord       Date:  2015-08-22       Impact factor: 4.652

3.  Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Authors:  José-Francisco Rocha; Amílcar Falcão; Ana Santos; Roberto Pinto; Nelson Lopes; Teresa Nunes; Lyndon C Wright; Manuel Vaz-da-Silva; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2014-06-14       Impact factor: 2.953

4.  Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.

Authors:  Pedro Silveira; Manuel Vaz-da-Silva; Luis Almeida; Joana Maia; Amilcar Falcão; Ana Loureiro; Leonel Torrão; Rita Machado; Lyndon Wright; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2003-09-27       Impact factor: 2.953

5.  Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Authors:  José Francisco Rocha; Luis Almeida; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

6.  Catecholamine synthesis and metabolism in the central nervous system of mice lacking alpha-adrenoceptor subtypes.

Authors:  M A Vieira-Coelho; M P Serrão; J Afonso; C E Pinto; E Moura
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

7.  Effect of moderate liver impairment on the pharmacokinetics of opicapone.

Authors:  José Francisco Rocha; Ana Santos; Amílcar Falcão; Nelson Lopes; Teresa Nunes; Roberto Pinto; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2013-11-24       Impact factor: 2.953

8.  Interspecies comparison in the COMT-mediated methylation of 3-BTD.

Authors:  Yangliu Xia; Huilin Pang; Tongyi Dou; Ping Wang; Guangbo Ge
Journal:  RSC Adv       Date:  2018-05-01       Impact factor: 3.361

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.